December 11, 2017 12:53 PM ET

Biotechnology

Company Overview of Eurogentec S.A.

Company Overview

Eurogentec S.A. manufactures and distributes reagents, kits, and specialty products to life science, diagnostic, and pharmaceutical markets. Its life science research business unit provides R&D laboratories with reagents and related services for genomics and proteomics. The company offers oligonucleotides; qPCR and qRT-PCR kits, qPCR consumables, and dispensing services; peptides; antibodies that include custom polyclonals and monoclonals, and catalogue antibodies; and other biochemicals, such as PCR and RT-PCR, DNA extraction and purifications kits, electrophoresis, transformation, protein production and analysis, and synthesis reagent products. It also provides good manufacturing practices...

LIEGE Science Park

Rue du Bois Saint Jean 5

Seraing,  4102

Belgium

Founded in 1985

Phone:

32 4 372 74 00

Fax:

32 4 365 16 04

Key Executives for Eurogentec S.A.

Chief Executive Officer and Director
Age: 67
Head of Finance
Chairman of The Board and Chief Operation Officer
Human Resources Director
Biologics Business Unit Director
Compensation as of Fiscal Year 2017.

Eurogentec S.A. Key Developments

Eurogentec S.A. Presents at BIO Europe 2016 Conference, Nov-07-2016

Eurogentec S.A. Presents at BIO Europe 2016 Conference, Nov-07-2016 . Venue: KoelnMesse - Congress Center North, Cologne, Germany.

Scancell Holdings Announces Manufacture Agreement with Eurogentec S.A

Scancell Holdings PLC announced an agreement with Eurogentec S.A, an FDA inspected CMO specialised in the GMP production of plasmid DNA and recombinant proteins, for the manufacture of new supplies of Scancell's SCIB1 ImmunoBody® vaccine for use in the US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017. Upon completion and once fully evaluated, which is expected to take approximately 9-12 months, this clinical trial material will also be available to recommence dosing of patients in the company's long-term extension of the Phase 1/2 SCIB1 clinical study in malignant melanoma (subject to regulatory approval). Eurogentec's biologics division produces clinical trial and commercial biopharmaceutical material compliant with current Good Manufacturing Practice (cGMP) for all major markets according to US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) requirements. The company is FDA inspected (2011, 2013, 2014) and currently manufactures a biopharmaceutical marketed in the US. In the field of plasmid DNA, Eurogentec is a recognised leading CMO having recently manufactured 150g of plasmid DNA material for a major pharmaceutical company with plans to scale the process to commercial requirements.

Similar Private Companies By Industry

Company Name Region
ADx NeuroSciences NV Europe
Apitope International NV Europe
Beta-Cell NV Europe
Bienca S.A. Europe
Biopole S.A. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eurogentec S.A., please visit www.eurogentec.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.